In Vitro Fertilization (IVF)

To perform a systematic review and meta-analysis of obstetric and perinatal complications in singleton pregnancies after the transfer of frozen thawed and fresh embryos generated through IVF.|Systematic review.|Observational studies, comparing obstetric and perinatal outcomes in singleton pregnancies subsequent to frozen thawed ET versus fresh embryo transfer, were included from Medline, EMBASE, Cochrane Central Register of Clinical Trials, DARE, and CINAHL (1984-2012).|Women undergoing IVF/intracytoplasmic sperm injection (ICSI).|Two independent reviewers extracted data and assessed the methodological quality of the relevant studies using critical appraisal skills program scoring. Risk ratios and risk differences were calculated in Rev Man 5.1. Subgroup analysis was performed on matched cohort studies.|Antepartum hemorrhage, very preterm birth, preterm birth, small for gestational age, low birth weight, very low birth weight, cesarean section, congenital anomalies, perinatal mortality

All in vitro fertilization (IVF) programs and clinics should have a plan to protect fresh and cryopreserved human tissue (embryos, oocytes, sperm) and to provide for continuation of patient care in the event of an emergency or natural disaster. This document was reviewed and affirmed by the Practice Committee in 2011.

The Ethics Committee recommends development of evidence-based policies that are patient-centered for each in vitro fertilization (IVF) center. In most cases, the provision of futile therapies is not ethically justiable. For those treatments with very poor success rates, clinicians must be vigilant in their presentation of risks, benets, and alternatives. This document was reviewed in January 2012. This version replaces the previous version of this document, published in 2009.

To conduct a meta-analysis of studies assessing the effect of IVF and intracytoplasmic sperm injection (ICSI) on birth defects.|Meta-analysis.|Centers for reproductive care.|Patients treated by IVF and/or ICSI.|We identified all studies published by September 2011 with data related to birth defects in children conceived by IVF and/or ICSI compared with spontaneously conceived children, or birth defects in the children conceived by IVF compared with those by ICSI. Risk ratios from individual studies were pooled with the fixed and random effect models.|Risk of birth defects in children conceived by IVF and/or ICSI.|Of 925 studies reviewed for eligibility, 802 were excluded after screening titles and abstracts, 67 were excluded for duplicated data, data unavailable, or inappropriate control group, 56 were included in the final analysis. Among the 56 studies, 46 studies had data on birth defects in children conceived by IVF and/or ICSI (124,468) compared with spontaneously conceived

The objective of this article was to conduct a systematic review with meta-analysis of the trials of acupuncture during in vitro fertilization (IVF) or intracytoplasmic sperm injection (ICSI) treatment on the outcomes of clinical pregnancy, biochemical pregnancy, ongoing pregnancy, implantation rate, live birth, and miscarriage.|The search was conducted by using MEDLINE(), SCISEARCH, the Cochrane Menstrual Disorders and Subfertility Group trials register, AMED, Cumulative Index to Nursing and Allied Health Literature, EMBASE, Wanfang Database, China Academic Journal Electronic full text Database in China National Knowledge Infrastructure, Index to Chinese Periodical Literature, ISI Proceedings for conference abstracts, and ISRCTN Register and Meta-register for randomized controlled trials.|Study selection, quality appraisal, and data extraction were performed independently and in duplicate. The measures of treatment effect were the pooled relative risks (RR) of achieving clinical

Multi-Center, Randomized, Open-Label, Parallel Group Study of a Vaginal Micronized Progesterone Tablet ( Endometrin) Compared to Crinone 8 Vaginal Gel in Female Patients Undergoing In-Vitro Fertilization ( IVF).

The Effect of Acupuncture on Infertility With In-Vitro Fertilization ( IVF) Patients.

Protocols for Improved in Vitro Fertilization ( IVF) Outcomes. This study has been terminated. (

Full Text View. A Trial of Dehydroepiandrosterone ( DHEA) Treatment for in Vitro Fertilization ( IVF). ... Vitro Fertilization ( IVF).

Full Text View. Sibling Oocyte Study of Medium for In Vitro Fertilization/Intracytoplasmic Sperm Injection ( IVF/ICSI) With no Human Serum Albumine. ... In Vitro Fertilization. Infertility. Other: Medium with no human serum albumine added.

Elective single embryo transfer following in vitro fertilization.

The management of obstructive azoospermia: AUA best practice statement.

of in vitro fertilization ( IVF), to provide guidelines on the number of embryos to transfer in IVF-embryo transfer ( ET) in order to optimize healthy live births and minimize multiple pregnancies. ... Search terms included embryo transfer ( ET),

Search terms included assisted reproduction, assisted reproductive technology, ovulation induction, intracytoplasmic sperm injection ( ICSI), embryo transfer, and in vitro fertilization ( IVF). ... II-2A) 19. The clinical application of preimplantation

Ovulation induction in polycystic ovary syndrome.

Infertility

Online newsletter summarizing published findings from AHRQ-funded studies, new AHRQ publications and products, and funding opportunities.

This report presents key findings from the Agency for Healthcare Research and Quality's (AHRQ) research portfolio during 2008.

in the laboratory ( i.e., in vitro fertilization and related procedures). ... ART procedures include those infertility treatments in which both eggs and sperm are handled in the laboratory for the purpose of establishing a pregnancy ( i.e., in vitro

Topic page summarizing evidence report on effectiveness of assisted reproductive technology.

First, Plan B was only available OTC to women age 17 and up. In April, a judge ordered that it be made available to women of all ages. Now, an appeals court judge has stayed an order that would make a one-dose version of the emergency contraception available to all ages, while allowing the two-dose drug to be sold OTC without restriction. What do you make of all this?

muscle pain relief in Hong kong
eToims is a non-invasive pain therapy treatment for individuals desiring general physical health maintenance and enhancement or relief from chronic pain.Back pain is often caused or aggravated by bad or worn-out mattresses. A new pressure-relieving mattress and pillow can make a huge difference. It can support your back, shoulders and neck where it needs it most and thereby help you sleep in a better position, relieving pressure points and back pain. For more information on pressure relieving mattresses and pillows click here.For more information visit us at- Email-info@etoims.com,Contact- +1 215-387-0550.

For the past few months, I have not received any posts on the listserv OB-GYN-L. I would get daily posts in my e-mail. Where has it gone, what has happened to it? What can I do to get back on the list?

If anybody has any information, send me a note at:

dean@thehuffpeople.net


Dean Huffman

Pregnant woman and the newborn infant in breast feeding both of them need safety. So, caution in use of drugs in pregnancy and during lactation is mandatory. The knowledge of risk-benefit ratio of different drugs should be in mind of the doctor while prescribing a pregnant or lactating lady.Definitions of Pregnancy categories of drugs and a table showing pregnancy categories of drugs and safety of drugs in lactation are given here.

Definitions of Pregnancy categories of drugs:

On the basis of the potentiality for producing birth defects drugs in pregnancy are grouped into 1 of 5 categories which are A,B, C, D and X. Drugs of class A and B are considered safe and can be used routinely.

Pregnancy Category A : Controlled studies in pregnant women fail to detect risk to the fetus in the first trimester and no evidence of risk in later trimesters. The possibility of harm to the fetus appears remote by using the drugs of pregnancy category A.

Pregnancy Category B : Presumed safety on the basis of animal studies, with no controlled study in pregnant women, or animal studies have shown an adverse effect which was not confirmed in controlled studies in women in the first trimester and there is no evidence of risk to the fetus in later trimesters.

Pregnancy Category C : Studies in women and animals are not available or studies in animals have shown adverse effects on the fetus and there is no controlled study in women. Drugs should be given in pregnancy only if the potential benefits justify the potential risk to the fetus.

Pregnancy Category D : There is positive evidence of risk to the human fetus (unsafe), however in a life-threatening illness the potential risk may be justified if there are no other alternatives.

Pregnancy Category X : Highly unsafe: risk of use outweighs any potential benefit. Drugs in this category are contraindicated in pregnant women or in a woman who may become pregnant. To get more please visit -
http://medicalforall.net/drugs-pregnancy-lactation/

Recently, I had the occasion to review a case of a term primigravida with PROM in a private hospital (no housestaff or in house obstetricians). She was seen by an obstetrician soon after arrival, evaluated, and pitocin induction begun.

She did not deliver for around 29 hours after admission, and the delivering obstetrician (a different physician) was physically present during the last 2 hours of labor prior to delivery.

Simply put, while the two involved obstetricians were in communication by phone with the nursing staff throughout labor (separately as their "shifts" did not overlap), no one actually came to the bedside and wrote a note) from admission until around 2 hours before delivery.

Medical staff bylaws call for a daily progress note; this bylaw was easily met.

In reviewing the case, it did not "feel good" that no one came to the bedside.

My questions:

1. Does anyone have or know of any guidelines to mandate such bedside attendance? Of course, we all hope that the involved physicians would not need said guidelines.
2. Does anyone have a suggestion of hospital/nursing protocols? Simply, in this case I would like to have had a charge nurse or bedside nurse simply say, "Hey, no one has been by for a while. What's up?"

Garry

Reviews Of Progress is a weekly peer-reviewed scientific journal that covers original research and reviews. It publishes all articles under the guidance of the editorial team. The current Editor-in-Chief is Pindipol S.I, the editorial office is in Solapur.

I helped another physician with removal of a retained placenta last night, we were unsuccessful in removing it vaginally, her cervix was too closed to allow manual removal and we could only get a few pieces out with ring forceps and a large curette, so we did a laparotomy/hysterotomy and were able to preserve the uterus. The placenta turned out not to be an accreta and it was easily removed via that route through a low vertical incision on the uterus. Any thoughts on the appropriate CPT code would be appreciated. The patient came in through the ER five days after home delivery by her husband. She was severely anemic, rcvd 7 units of blood and is still quite ill and in the ICU but improving.

Ronald E. Ainsworth, MD, FACOG

Hello,

Has anyone tried FetalGrowth app (App Store for iPhone/iPad) ? I'm interested in using a simple and handy tool to calculate fetal percentiles, and I came across this app, which seems it does the job (plots growth charts, as well). I haven't seen anything else, besides this app, so I was wondering if there are people who have already tried it.

Thanks !

Had a case the other day with the above finding on a pap. She was age 36 and had a Mirena in place. How do people feel about the idea of trying to do an EMB with an IUD in place? If not, how do we proceed?

Welcome to the new ObGyn.net Forum!

To all the members of OB-GYN-L… Thank you for coming! I’m thrilled that you’ve decided to check out the new Forum site, and look forward to reading about what’s on your mind.

If you’re new to the ObGyn.net community... welcome aboard! You’ve just joined an outstanding group of physicians and health care professionals who have been sharing information, answering questions, and building professional relationships via the site’s listserv for nearly 20 years.

Feel free to poke around on the site to get a feel for things, or take a look at the Help Topics page for instructions on how to use the different features of the site.

A few quick tips:
For those of you who like getting new Forum messages delivered directly to your inbox, the first thing you’ll want to do is click on the ‘Follow this forum’ button on the main page. You’ll have the option of getting notifications immediately, as a daily digest, a weekly digest, or only when you’re not online (which is to say, if you’re on the site when someone posts a message, you won’t be notified of it). You won’t be able to post on the site just by replying to the email, but the message will contain a link that takes you directly to the message you’d like to reply to.

You can also follow individual conversations without following the whole list by going into the topic and clicking the ‘Follow this topic’ button next to the title.

Also, in ‘My Profile’ you can:

• Enter your professional information, including specialty, subspecialty, and education (by clicking ‘Edit my profile’)
  
• See your activity on the Forum, such as what discussions you have initiated or replied to, content you’ve ‘liked,’ and activity of people you’ve made your friends

In ‘My Settings’ you can:

• Add or change your photo
  
• Edit your birthday, gender, interests, location
  
• Create a signature for your posts
  
• Change the types of content you get notifications for, or change the way you receive notifications

If you have questions, feel free to respond to this post or send me a direct message by clicking on the envelope icon.

Happy posting!